Jaguar Animal Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Animal Health, Inc. on November 22, 2016. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
The Company entered into a securities purchase agreement to sell equity to institutional investors. Key terms include:
- Common Stock Sale: 1,666,668 shares at $0.60 per share.
- Gross Proceeds: Approximately $1.0 million.
- Warrants Issued:
- Series A: 1,666,668 shares at $0.75 exercise price (5-year term).
- Series B: 1,666,668 shares at $0.90 exercise price (6-month term).
- Series C: 1,666,668 shares at $1.00 exercise price (1-year term).
- Potential Warrant Proceeds: Approximately $4.4 million if fully exercised on a cash basis.
- Placement Agent Fees: 8.0% of gross proceeds plus up to $65,000 for legal expenses.
- Placement Agent Warrants: 133,333 shares at $0.75 exercise price.
The filing does not provide current revenue, profit, cash flow, or debt metrics as this is a transactional report rather than a periodic financial statement.
Material Changes and Obligations
The primary material change is the dilution of existing shareholders through the issuance of new shares and warrants. The Company is obligated to file a registration statement for the resale of these securities within 10 business days of the pricing date. Failure to meet registration deadlines may result in liquidated damages.
Outlook, Risks, and Contingencies
Closing Date: Expected on or about November 29, 2016, subject to customary conditions.
Exercisability: Warrants are not exercisable until six months after issuance.
Ownership Limits: Warrants contain provisions preventing holders from acquiring more than 4.99% (or 9.99% with notice) of outstanding common stock upon exercise.
Risks: The filing includes standard forward-looking statement disclaimers regarding the proposed offering, proceeds, and closing date, noting these are subject to uncertainties and risks beyond the Company's control.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $1.0 million gross proceeds.
- Review the definitive Registration Rights Agreement (Exhibit 10.2) for specific liquidated damages clauses.
- Monitor the filing of the registration statement for resale of securities within the required 10-business-day window.
- Assess the impact of the 8.0% placement fee and legal expense reimbursement on net proceeds.
- Confirm the total number of shares outstanding post-closing to calculate the exact dilution impact.